Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions comprising human antibodies to PCSK9

A composition and drug technology, applied to the inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase, in the field of treating diseases or conditions affected by the expression or activity of PCSK9, and can solve the problem of low target achievement rate And other issues

Inactive Publication Date: 2013-12-25
SANOFI BIOTECH
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, since the most effective lipid-lowering agents can only lower LDL-C levels by up to 55%, target achievement rates in patients requiring substantial LDL-C lowering, such as those with familial hypercholesterolemia (target attainment rate) is often significantly lower than can be expected

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising human antibodies to PCSK9
  • Pharmaceutical compositions comprising human antibodies to PCSK9
  • Pharmaceutical compositions comprising human antibodies to PCSK9

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0142] The present invention will now be further described. The different aspects of the invention are defined in more detail in the following paragraphs. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous unless clearly indicated to the contrary.

[0143] In a first aspect, the invention relates to a pharmaceutical composition comprising about 40 to about 500 mg of an antibody that specifically binds proprotein convertase subtilisin / kexin type 9 (PCSK9) together with a pharmaceutically acceptable excipient or carrier.

[0144] Suitable antibodies or fragments thereof for practicing the first aspect are described in the "Preferred Antibodies for Practicing the Invention" section. Preferred embodiments of the antibody or fragment thereof are describ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Bmiaaaaaaaaaa
Login to View More

Abstract

The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin / KEXIN type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin / KEXIN type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition comprising a proprotein convertase subtilisin / kexin type 9 (proprotein convertase subtilisin / kexin type 9, PCSK9) specific antibody or an antigen-binding fragment thereof, preferably, it comprises 3-hydroxy-3-formazan Inhibitors of HMG-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to injection solutions, dry formulations and unit dosage forms comprising PCSK9-specific antibodies or antigen-binding fragments thereof and their use for the treatment of diseases or conditions in which PCSK9 expression or activity is affected (preferably in combination with HMG-CoA reductase combination of inhibitors). [0002] The invention also relates to an article of manufacture comprising packaging material, a PCSK9-specific antibody or antigen-binding fragment thereof, and a label or package insert indicating, for example, which groups of patients may be treated with th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/40A61K39/395A61P3/06
CPCC07K16/40G01N33/92C07K2317/76C07K2317/21G01N2800/044A61K2039/505A61K31/215A61K31/366A61K31/404A61K31/435A61K31/47A61K31/505A61P3/00A61P3/06A61P43/00A61P5/00A61P7/00A61P9/00A61P9/10A61J1/05A61K39/3955A61K39/395C07K14/4703A61K45/06A61K2039/545A61K39/00
Inventor C.哈诺廷L.贝萨克U.乔哈里
Owner SANOFI BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com